Abstract Library

#3036 Can Ki-67 with 5.5% Be Better in Predicting Prognosis for Well Differentiated Pancreatic Neuroendocrine Tumors?

Introduction: Pancreatic neuroendocrine tumors (NETs) are rare malignancies, Ki-67 is a cell proliferation marker that has been shown to have some utility in predicting prognosis of neuroendocrine tumors. However, the ideal grading method for G1/G2 remains controversial.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Tan H

Authors: Yuan B, Chen Y, Zhang P, Wang X, Tan H,

Keywords: Pancreatic net, G1, G2, Ki-67, overall survival time,

#2899 Using Long-Acting Somatostatin Analogue as Adjuvant Therapy for Post Resection Grade 2 Pancreatic Neuroendocrine Tumor: Interim Results from an Ongoing Multicenter Real-World Study in China

Introduction: Surgery was the preferred treatment in patients with resectable pancreatic neuroendocrine tumor (pNET), but recurrent lesion relapsed frequently within a short time. It was controversial whether patients with pNET need adjuvant therapy after surgery.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Shi X

Authors: Shi X, Xu X, Zhang Y, Gao S, Li B,

Keywords: somatostatin analogue, adjuvant therapy, pancreatic neuroendocrine tumor,

#2876 Efficacy of Surufatinib in Western Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNETs)

Introduction: Surufatinib is a targeted inhibitor of tyrosine kinases VEGFR1, 2, & 3, FGFR1, and CSF-1R. The safety profile was favorable in 2 completed studies (NCT02133157, NCT02267967) conducted in China. A recent phase 3 placebo controlled study (NCT02588170) confirmed safety, and demonstrated superior efficacy (PFS: 9.2 v 3.8 months) of Surufatinib in Chinese pts with advanced extra-pancreatic NETs (epNET).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Dasari A, Paulson S, Sung M, Tucci C, Kauh J,

Keywords: Neuroendocrine Tumors, Pancreatic, Surufatinib,

#2857 Clinical Epidemiology Study of Rectal Neuroendocrine Neoplasms in China: A National Multicenter 10-Year Retrospective Study

Introduction: Representative data on the rectal neuroendocrine neoplasms in Chinese patients is rare.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Huan Y

Authors: Jinhu F, Yihebali C, Huan Y, Su Z, Susheng S,

Keywords: rectal neuroendocrine neoplasms, clinical features, epidemiology,

#2850 A Clinical Controlled Observation of Chinese Herbal Decoction (SMLJ01) for Type 1 Gastric Neuroendocrine Neoplasms

Introduction: Type 1 gastric neuroendocrine neoplasms (g-NENs) usually have good prognosis, however, most patients(pts) experience the recurrence after endoscopic resection.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Tan H

Authors: Chen Y, Han D, Zhu J, Chen J, Hu H,

Keywords: type 1 g-NENs, recurrence, Chinese herbs,